Pharmathen acquires CBL Patras
Utility of Trityl Supports in Fmoc-t-butyl Solid Ph Peptide Synthesis
(Reuters) - A total of 316 cases of rare blood clots with low platelets have been recorded in adults who received AstraZeneca’s COVID-19 vaccine in the European Economic Area, an executive of the region’s drug regulator said.
Global Pharmaceutical Packaging Machines Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.
CBL, the “Peptide Innovators” was recently inspected both by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Approvals were received from both agencies for the API manufacturing of octreotide. This drug is used in the treatment of various cancers.
BENSHEIM, Germany and PATRAS, Greece, December 16, 2020 / B3C newswire / -- Relaxera Pharmazeutische Gesellschaft mbH & Co. KG and CBL Patras (Chemical and Biopharmaceutical Laboratories) announce the signing of an exclusive contract for human relaxin-2.
Comparison of Fmoc-(Trt) and Fmoc-(t-Bu) Amino Acid Protection
D-Amino Acids at CBL
The Abundant Versatility of the 4-Methoxytrityl Group
Usage of Trityl Linkers